Marc Shenouda is the CEO and Co-Founder of Neuropeutics Inc., a pharmaceutical company focused on developing therapies to improve the quality of life and extend the survival of patients with neurodegenerative diseases. He holds a PhD from Laboratory Medicine and Pathobiology from the University of Toronto. Marc participated in the CDL-Neuro stream in 2024 cohort. 

Lahav Gil – medtech entrepreneur, executive and investor

Lahav Gil is a Canadian-Israeli medtech entrepreneur, executive and investor with deep roots in technology, design and operations. Lahav began his career in the late 80s as an industrial designer in the Israeli technology sector before immigrating to Canada in 2000. He brings over three decades of experience as a founder, technology innovator, entrepreneur, executive and investor, primarily in the medtech space.

Throughout his career, Lahav has contributed to the development and launch of over 200 technology products. He has founded several companies and successfully sold two. Most notably, he founded the Kangaroo Group (ISO 13485) building it into a major Canadian brand for medtech innovation, contract manufacturing, and startup acceleration. In 2017, Lahav sold Kangaroo to its main competitor, Starfish Medical. During the seven years prior to selling, he transformed the Kangaroo Group into a private incubator, deploying the company’s know-how and infrastructure as investment capital into startups. After selling Kangaroo, he orchestrated successful turnarounds at Relay Medical and UX Data Sciences.

Throughout his career, Lahav has advised numerous startups in both official and informal capacities. He currently serves as CEO at Arma Biosciences and chairs the board of Pulsemedica. He also co-founded a mountain bike startup with his son Ariel.

Lahav is a Creative Destruction Lab (CDL) mentor in the Neuro and Biomedical Engineering streams, and operates as a mentor-angel to startup CEOs. In this capacity, he helps them advance science and technology into products with meaningful clinical utility while building investable, acquirable companies. Most importantly, he works with founders on their transition from a technology focus to a clinical and business-journey focus.

Lahav is the author of the Cathedral Framework, a stakeholder-centric systems approach to life-sciences venture design and building. He splits his time between Toronto and Tel Aviv. Lahav is deeply interested in a thriving future for humanity, sustainability, ethics, values-based leadership, awareness and innovation culture.

Dr. Kyla Alsbury-Nealy | Co-Founder & COO, Silico Labs 

BASc in Organismal Biology & International Development, MSc in Physical Therapy, PhD In Rehabilitation Sciences 

Healthcare Innovator | Expert in Immersive Technology and Behavioral Analytics | Advocate for Translational Research 

Kyla Alsbury-Nealy is a trailblazer in healthcare innovation, bringing over a decade of clinical experience as a physical therapist and a PhD in Rehabilitation Sciences from the University of Toronto to her role as Co-Founder and Chief Operating Officer of SilicoLabs. With a passion for advancing health research and improving patient outcomes, Kyla has dedicated her career to bridging the gap between knowledge translation and clinical practice. 

During her PhD, Kyla recognized a critical need for tools that provide more accurate and actionable insights into health conditions. Traditional self-reported data often failed to capture true behaviours, motivating her to co-develop LABO, a no-code behavioural analytics platform that enables researchers to design immersive, real-world simulations. These tools offer unparalleled insights into conditions such as cognitive impairment, concussion, and stroke, transforming how health data is collected and understood. 

As COO of SilicoLabs, Kyla combines her scientific expertise and strategic leadership to drive the company’s growth and innovation. She excels at optimizing operations, aligning business strategies with technological advancements, and fostering a collaborative, forward-thinking culture. Her ability to translate complex research into practical, scalable solutions positions SilicoLabs as a leader in the field of immersive technology for health research. 

Kyla’s academic journey began with a BASc in Organismal Biology and International Development Studies from McGill University, followed by an MSc in Physical Therapy from Queen’s University. Her diverse expertise and unwavering commitment to healthcare innovation continue to redefine how researchers and clinicians approach health and wellness. For those looking to explore groundbreaking collaborations in health technology, Kyla is a visionary leader eager to shape the future of immersive research. 

Dr. Daniel Szulc | Chief Product Officer, OXcan (Oxford Cancer Analytics)  

Daniel Szulc is a chemist turned engineer with a passion for innovation, collaboration, and communication. After completing a double major in physiology and chemistry he went on to achieve a doctorate in biomedical engineering at the University of Toronto, where he was recognized as a UofT Top Scholar and Graduate to Watch for his impact as a STEM innovator and role model. His academic and industrial research spans the fields of biology, chemistry, medicine and physics and has led to several peer-reviewed manuscripts, inventions and collaborative projects awarded millions of research funding geared towards clinical translation. Currently, as the Chief Product Officer at Oxford Cancer Analytics (OXcan) he is focused on enabling curative cancer treatments through early detection. At OXcan he targets the unexplored gaps in cancer management by looking at the intersection of high-throughput multi-omics and machine learning with an emphasis on proteins to discover previously unknown biomarkers for unprecedented cancer early detection accuracy.